Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) used to treat primary hyperoxaluria type1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.The recommended dosing regimen of Oxlumo consists of loading doses followed by maintenance doses. The recommended dose of Oxlumo by subcutaneous injection is based on the patient’s body weight.